Skip to main content
Fig. 1 | Respiratory Research

Fig. 1

From: Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator

Fig. 1

Patient disposition and flow. AE = adverse event; PK = pharmacokinetic. aFive patients discontinued due to treatment emergent AEs leading to study drug discontinuation, 1 patient withdrew due to a treatment emergent AE during the washout period, and 1 withdrew due to a non-treatment-emergent AE; bpatient had a positive drug screen test for cocaine; cpatient did not meet stability/variability criteria

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us